Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

Table 3

Details of multivariate analysis for progression-free survival.

Variable	Hazard ratio	value on Cox regression analysis
	1.710 (0.486–6.019)	0.430
ECOG PS	0.354 (0.98–1.288)	0.115
Smoking status	1.474 (0.671–3.239)	0.334
Brain metastasis	0.932 (0.416–2.090)	0.865
EGFR mutation type	0.563 (0.272–1.164)	0.121

was defined as age of 65 years or above.